Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks SUBLOCADE users for 4 years to see if recovery lasts

NCT ID NCT05860959

Disease control Sponsor: Indivior Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study followed 480 adults with opioid use disorder who were already taking SUBLOCADE, a long-acting buprenorphine injection. Researchers observed participants for up to 4 years to see if they achieved remission, reduced opioid misuse, and improved their physical, mental, and social well-being. The goal was to understand what helps people recover in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SUBLOCADE (buprenorphine extended-release injection)
What this could lead to
If successful, this study could show that long-term SUBLOCADE use helps people with opioid use disorder achieve and maintain remission, improving their overall health and quality of life.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. Participants are already on SUBLOCADE, and outcomes depend on many personal factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

480 people

The number who actually took part.

Started

Aug 2023

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants may enroll if they have initiated treatment with SUBLOCADE within 3 months prior to signing the informed consent form (ICF), or have completed an Indivior SUBLOCADE study (eg, INDV-6000-401, INDV-6000-405) and received their last dose of SUBLOCADE on the study within 3 months prior to signing the ICF, and plan to receive additional SUBLOCADE injections.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet all of the following criteria: * Is an adult ≥ 18 years of age who has signed the informed consent form * Plans to receive additional SUBLOCADE injections and * Has initiated treatment for OUD/opioid dependence with SUBLOCADE within the last 3 months prior to Baseline Visit * OR * Has completed an Indivior SUBLOCADE study (eg, INDV-6000-401, INDV-6000-405) and has received the last dose of SUBLOCADE on that study within 3 months prior to Baseline Visit * Is not currently participating in any clinical trial requiring medical intervention * Is not currently using opioids to treat a diagnosis other than OUD/opioid dependence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid-use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid-use disorder

Contacts and locations

Locations

  • ATP Clinical Research

    Costa Mesa, California, 92626, United States

  • Alpine Research Organization

    Clinton, Utah, 84015, United States

  • Atlanta VA Medical Center

    Decatur, Georgia, 30033-4004, United States

  • Baystate Health

    Springfield, Massachusetts, 01199, United States

  • Beroendecentrum

    Stockholm, SE-11365, Sweden

  • Biopharma Informatic, Inc. Research Center

    Houston, Texas, 77043, United States

  • Bluewater Rapid Assessment Addiction Medicine Clinic

    Sarnia, Ontario, N7T 5W9, Canada

  • Brightshores Health System

    Owen Sound, Ontario, N4K 6M9, Canada

  • Charleston Pain and Rehabilitation Center

    Charleston, South Carolina, 29407, United States

  • Collective Medical Research.

    Prairie Village, Kansas, 66210, United States

  • Comprehensive Treatment Clinic

    Toronto, Ontario, M4J 1M3, Canada

  • Core Clinical Trials

    North New Hyde Park, New York, 11042, United States

  • DENT Neurologic Institute

    Amherst, New York, 14226, United States

  • Dr. J.S. Dhillon Medicine Prof. Corp

    Burlington, Ontario, L7M 4X9, Canada

  • Drug and Alcohol Services South Australia (DASSA)

    Stepney, South Australia, 5069, Australia

  • Elevate Health and Wellness

    Westport, Connecticut, 06880, United States

  • Fraser Health Authority

    Surrey, British Columbia, V3T 0H1, Canada

  • G+C Research Group

    Miami, Florida, 33134, United States

  • Healing Comfort Clinic, LLC

    Corvallis, Oregon, 97330, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Jackson Health Community Center

    Miami, Florida, 33126, United States

  • John Hunter Hospital

    Newcastle, New South Wales, 2300, Australia

  • Linkoping University Hospital, Psychiatry Center

    Linköping, 58185, Sweden

  • Maine Health

    Scarborough, Maine, 04074-7163, United States

  • Maryland Treatment Centers

    Baltimore, Maryland, 21229, United States

  • Midlands Neurology

    Columbia, South Carolina, 29205, United States

  • Neighborhood Healthcare-Institute of Health

    Escondido, California, 92025, United States

  • North Mississippi Medical Center

    Tupelo, Mississippi, 38801, United States

  • North Point Medical Center

    Fair Haven, Michigan, 48023, United States

  • Onsite Clinical Solutions LLC

    Charlotte, North Carolina, 28277, United States

  • Pahl Pharmaceutical Professionals LLC

    Oklahoma City, Oklahoma, 73112, United States

  • Prisma Health

    Greenville, South Carolina, 29605, United States

  • Psych Care Consultants

    St Louis, Missouri, 63141-8704, United States

  • Recovery Alberta

    Edmonton, Alberta, T5J 3E4, Canada

  • SHMG Center for Integrative Medicine

    Grand Rapids, Michigan, 49503-4224, United States

  • Smart Clinic

    Calgary, Alberta, T2E2R2, Canada

  • St Vincent's Hospital Melbourne

    Fitzroy, Melbourne, 3065, Australia

  • Stuart Wasser Practice

    Rockville Centre, New York, 11570, United States

  • THRYV Clinical Studies

    Dearborn, Michigan, 48124, United States

  • Thalia Medical Centre

    Narberth, Pennsylvania, 19072, United States

  • The Stipley Clinic

    Hamilton, Ontario, L8N 1H3, Canada

  • Turning Point

    Richmond, VIC 3121, Australia

  • United Health Services

    Binghamton, New York, 13903, United States

  • United Research Institute

    Hialeah, Florida, 33012, United States

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • Vida Clinical Studies

    Dearborn Heights, Michigan, 48127, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23219, United States

  • Wayne State University Hospital

    Detroit, Michigan, 48201, United States

  • Zenith Clinical Research LLC

    Hollywood, Florida, 33021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.